282 related articles for article (PubMed ID: 25784657)
1. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
Jackman DM; Cioffredi LA; Jacobs L; Sharmeen F; Morse LK; Lucca J; Plotkin SR; Marcoux PJ; Rabin MS; Lynch TJ; Johnson BE; Kesari S
Oncotarget; 2015 Feb; 6(6):4527-36. PubMed ID: 25784657
[TBL] [Abstract][Full Text] [Related]
2. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
[TBL] [Abstract][Full Text] [Related]
5. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M
Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
[TBL] [Abstract][Full Text] [Related]
11. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Takahashi K; Saito H; Hasegawa Y; Ando M; Yamamoto M; Kojima E; Sugino Y; Kimura T; Nomura F; Ogasawara T; Shindoh J; Yoshida N; Suzuki R
Cancer Chemother Pharmacol; 2014 Oct; 74(4):721-7. PubMed ID: 25087097
[TBL] [Abstract][Full Text] [Related]
12. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
13. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
14. A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Yamada K; Aono H; Hosomi Y; Okamoto H; Kato T; Komase Y; Nishikawa M; Azuma K; Takeoka H; Okuma Y; Nakahara Y; Sato A; Oba MS; Morita S; Kunitoh H; Watanabe K
Eur J Cancer; 2015 Sep; 51(14):1904-10. PubMed ID: 26174465
[TBL] [Abstract][Full Text] [Related]
15. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF
Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
Damyanov D; Koynov K; Naseva E; Bichev S
J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
[TBL] [Abstract][Full Text] [Related]
19. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Song Z; Zhang Y
J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
